Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study
Authors:
- Chrystel IscaCIChrystel Isca
- Amelia SpinellaASAmelia Spinella
- Angela TossATAngela Toss
- Marco de PintoMPMarco de Pinto
- Guido FicarraGFGuido Ficarra
- Luca FabbianiLFLuca Fabbiani
- Anna IannoneAIAnna Iannone
- Luca MagnaniLMLuca Magnani
- Federica LumettiFLFederica Lumetti
- Pierluca MacripòPMPierluca Macripò
- Caterina VacchiCVCaterina Vacchi
- Elisa GaspariniEGElisa Gasparini
Open Access
- 3 December 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (12) , 2007
Abstract
Several authors reported an increased risk of cancer in SSc patients, including breast cancer (BC). Nevertheless, the mechanisms underlying this association have not yet been clarified. SSc and BC share several molecular pathways, which seem to play a common etiopathogenetic role. The previously published Sclero-Breast study demonstrated the development of BC with a good prognosis among these patients, which could be explained by an autoimmune background as a possible mechanism for limiting tumor extension. Here, we report the results of an IHC analysis of molecular pathways known to be common drivers for both diseases, with the aim to better define the mechanisms underlying a good prognosis of BC in patients affected by SSc. The analysis demonstrated higher TILs rates in all BC subgroups, with a high rate of PD-L1 expression especially in TNBC and HER2-positive BC, suggesting a less aggressive behavior in these patients compared to the general population. These results support a possible de-escalation strategy of cancer therapies in these fragile patients. These data could represent a starting point for future prospective studies based on the clinical application of these biomarkers with a larger sample size to promote a personalized and targeted oncological treatment for this specific subset of patients.Keywords
This publication has 45 references indexed in Scilit:
- The risk of cancer development in systemic sclerosis: A meta-analysisCancer Epidemiology, 2013
- Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studiesRheumatology, 2012
- Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancerBreast Cancer Research, 2012
- Abrogating endocrine resistance by targeting ERα and PI3K in breast cancerFrontiers in Oncology, 2012
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Review of Anticancer Therapy, 2011
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancerJournal of Clinical Investigation, 2010
- Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T CellsClinical Cancer Research, 2010
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Angiogenesis and vasculogenesis in systemic sclerosisRheumatology, 2006
- Overview of pathogenesis of systemic sclerosisRheumatology, 2006